International Journal of Radiation Oncology * Biology * Physics
Volume 53, Issue 2 , Pages 422-433 , 1 June 2002

Biologically effective dose for permanent prostate brachytherapy taking into account postimplant edema

  • Marion P.R. Van Gellekom (M.Sc.)

      Affiliations

    • Corresponding Author InformationReprint requests to: Marion P.R. Van Gellekom, M.Sc., Department of Radiotherapy, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands. Tel: +31-30-2509863; Fax: +31-30-2581226
    • Department of Radiotherapy, University Medical Center Utrecht, Utrecht, The Netherlands
  • ,
  • Marinus A. Moerland, Ph.D.

      Affiliations

    • Department of Radiotherapy, University Medical Center Utrecht, Utrecht, The Netherlands
  • ,
  • Henk B. Kal (Ph.D)

      Affiliations

    • Department of Radiotherapy, University Medical Center Utrecht, Utrecht, The Netherlands
  • ,
  • Jan J. Battermann, M.D., Ph.D.

      Affiliations

    • Department of Radiotherapy, University Medical Center Utrecht, Utrecht, The Netherlands

Received 13 September 2001 ,Revised 3 January 2002 ,Accepted 24 January 2002.

References 

  1. Nag S, Beyer D, Friedland J, et al.  American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys. 1999;44:789–799
  2. Nag S, Baird M, Blasko J, et al.  American Brachytherapy Society survey of current clinical practice for permanent brachytherapy of prostate cancer. J Brachytherapy Int. 1997;13:243–251
  3. Ling CC. Permanent implants using Au-198, Pd-103 and I-125 (Radiobiological considerations based on the linear quadratic model). Int J Radiat Oncol Biol Phys. 1992;23:81–87
  4. Holm HH, Juul N, Pedersen JF, et al.  Transperineal iodine-125 seed implantation in prostatic cancer guided by transrectal ultrasonography. J Urol. 1983;130:283–286
  5. Moerland MA. The effect of edema on postimplant dosimetry of permanent iodine-125 prostate implants (A simulation study). J Brachytherapy Int. 1998;14:225–231
  6. Moerland MA, Wijrdeman HK, Beersma R, et al.  Evaluation of permanent I-125 prostate implants using radiography and magnetic resonance imaging. Int J Radiat Oncol Biol Phys. 1997;37:927–933
  7. Waterman FM, Yue N, Corn BW, et al.  Edema associated with I-125 or Pd-103 prostate brachytherapy and its impact on post-implant dosimetry (An analysis based on serial CT acquisition). Int J Radiat Oncol Biol Phys. 1998;41:1069–1077
  8. Dale RG, Jones B, Coles IP. Effect of tumour shrinkage on the biological effectiveness of permanent brachytherapy implants. Br J Radiol. 1994;67:639–645
  9. Willins J, Wallner K. CT-based dosimetry for transperineal I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys. 1997;39:347–353
  10. Roy JN, Wallner KE, Harrington PJ, et al.  A CT-based evaluation method for permanent implants (Application to prostate). Int J Radiat Oncol Biol Phys. 1993;26:163–169
  11. Grimm PD, Blasko JC, Ragde H. Ultrasound-guided transperineal implantation of iodine-125 and palladium-103 for the treatment of early-stage prostate cancer (Technical concepts in planning, operative technique, and evaluation). Atlas Urol Clin North Am. 1994;2:113–125
  12. Narayana V, Roberson PL, Pu AT, et al.  Impact of differences in ultrasound and computed tomography volumes on treatment planning of permanent prostate implants. Int J Radiat Oncol Biol Phys. 1997;37:1181–1185
  13. Narayana V, Roberson PL, Winfield RJ, et al.  Impact of ultrasound and computed tomography prostate volume registration on evaluation of permanent prostate implants. Int J Radiat Oncol Biol Phys. 1997;39:341–346
  14. Yue N, Chen Z, Peschel R, et al.  Optimum timing for image-based dose evaluation of I-125 and Pd-103 prostate seed implants. Int J Radiat Oncol Biol Phys. 1999;45:1063–1072
  15. Chen Z, Yue N, Wang X, et al.  Dosimetric effects of edema in permanent prostate seed implants (A rigorous solution). Int J Radiat Oncol Biol Phys. 2000;47:1405–1419
  16. Barendsen GW. Dose fractionation, dose rate and iso-effect relationships for normal tissue responses. Int J Radiat Oncol Biol Phys. 1982;8:1981–1997
  17. Dale RG. The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy. Br J Radiol. 1985;58:515–528
  18. Dale RG. Radiobiological assessment of permanent implants using tumour repopulation factors in the linear-quadratic model. Br J Radiol. 1989;62:241–244
  19. Antipas V, Dale RG, Coles IP. A theoretical investigation into the role of tumour radiosensitivity, clonogen repopulation, tumour shrinkage and radionuclide RBE in permanent brachytherapy implants of I-125 and Pd-103. Phys Med Biol. 2001;46:2557–2569
  20. Dale RG, Jones B. The assessment of RBE effects using the concept of biologically effective dose. Int J Radiat Oncol Biol Phys. 1999;43:639–645
  21. Nath R, Anderson LL, Luxton G, et al.  (GRP) Dosimetry of interstitial brachytherapy sources (Recommendations of the AAPM Radiation Therapy Committee Task Group No. 43). Med Phys. 1995;22:209–234
  22. Fowler J, Chappell R, Ritter M. Is α/β for prostate tumors really low?. Int J Radiat Oncol Biol Phys. 2001;50:1021–1031
  23. King CR. What is the Tpot for prostate cancer? Radiobiological implications of the equivalent outcome with I-125 or Pd-103. Int J Radiat Oncol Biol Phys. 2000;47:1165–1167
  24. Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys. 1999;43:1095–1101
  25. Dicker AP, Lin C, Leeper DB, et al.  Isotope selection for permanent prostate implants? An evaluation of Pd-103 versus I-125 based on radiobiological effectiviness and dosimetry. Semin Urol Oncol. 2000;18:152–159
  26. Haustermans KMG, Hofland I, Van Poppel H, et al.  Cell kinetic measurements in prostate cancer. Int J Radiat Oncol Biol Phys. 1997;37:1067–1070

 Supported by the J. A. Cohen Institute for Radiopathology and Radiation Protection, Leiden, The Netherlands.

PII: S0360-3016(02)02755-4

International Journal of Radiation Oncology * Biology * Physics
Volume 53, Issue 2 , Pages 422-433 , 1 June 2002